Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1–STAT3/NF-κB signaling

Profound Actions of an Agonist of Growth Hormone–Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem CellsSignificance

(2016) QunChao Ma et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Gastric cancer

(2016) Eric Van Cutsem et al.   LANCET

Clinical impact of tumour biology in the management of gastroesophageal cancer

(2016) Florian Lordick et al.   Nature Reviews Clinical Oncology

PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2

(2016) H Dong et al.   ONCOGENE

Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients

(2016) A. Marcell Szász et al.   Oncotarget

PAK1 modulates a PPARγ/NF-κB cascade in intestinal inflammation

(2015) Kyle Dammann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dysregulation of PAK1 Is Associated with DNA Damage and Is of Prognostic Importance in Primary Esophageal Small Cell Carcinoma

(2015) Jinfeng Gan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MERAV: a tool for comparing gene expression across human tissues and cell types

(2015) Yoav D. Shaul et al.   NUCLEIC ACIDS RESEARCH

PAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesis

(2015) Guiling Wang et al.   Oncotarget

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers

(2015) Roberto Perez et al.   Oncotarget

Aberrant chimeric RNA GOLM1-MAK10 encoding a secreted fusion protein as a molecular signature for human esophageal squamous cell carcinoma

(2015) Hao Zhang et al.   Oncotarget

Tracing PAKs from GI inflammation to cancer

(2014) Kyle Dammann et al.   GUT

Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma

(2014) Zongtai Li et al.   INTERNATIONAL JOURNAL OF CANCER

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition

(2014) Wei Zhou et al.   JOURNAL OF PATHOLOGY

Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer

(2014) C. D. Fahrenholtz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation

(2014) Yong Jie Qin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling

(2014) Y Feng et al.   Cell Death & Disease

Resveratrol-induced apoptosis is enhanced by inhibition of autophagy in esophageal squamous cell carcinoma

(2013) Qishan Tang et al.   CANCER LETTERS

Gastric cancer—molecular and clinical dimensions

(2013) Roopma Wadhwa et al.   Nature Reviews Clinical Oncology

Prognostic Importance and Therapeutic Implications of PAK1, a Drugable Protein Kinase, in Gastroesophageal Junction Adenocarcinoma

(2013) Zongtai Li et al.   PLoS One

Targeting STAT3 in gastric cancer

(2012) Andrew S Giraud et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro

(2012) Agnieszka Siejka et al.   PEPTIDES

Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers

(2011) Anna Klukovits et al.   CANCER

GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells

(2011) Florian Hohla et al.   CELL CYCLE

Gene Expression Signature-Based Prognostic Risk Score in Gastric Cancer

(2011) J. Y. Cho et al.   CLINICAL CANCER RESEARCH

Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers

(2011) Shuet Theng Lee et al.   MOLECULAR CELL

Adapter Protein SH2B1β Binds Filamin A to Regulate Prolactin-Dependent Cytoskeletal Reorganization and Cell Motility

(2011) Leah Rider et al.   MOLECULAR ENDOCRINOLOGY

PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling

(2011) Y Shrestha et al.   ONCOGENE

Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia

(2011) Ferenc G. Rick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins

(2011) Anton Stangelberger et al.   PROSTATE

Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21

(2010) Hsien-Ming Wu et al.   CANCER LETTERS

GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro

(2010) Szabolcs Bellyei et al.   CANCER LETTERS

Growth hormone-releasing hormone: Extrapituitary effects in physiology and pathology

(2010) Nektarios Barabutis et al.   CELL CYCLE

The effect of GHRH antagonists on human glioblastomas and their mechanism of action

(2010) Eva Pozsgai et al.   INTERNATIONAL JOURNAL OF CANCER

Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells

(2010) Agnieszka Siejka et al.   PROSTATE

Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway

(2010) Jian Guo et al.   Reproductive Biology and Endocrinology

IKK/NF-κB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis

(2009) Julia Bollrath et al.   EMBO REPORTS

Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line

(2008) N. Barabutis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer

(2007) Andrew V Schally et al.   Nature clinical practice. Endocrinology & metabolism